# Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

> **NCT02988843** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 1 (actual)

## Conditions studied

- Germ Cell Tumor

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02988843
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-29
- **Primary completion:** 2019-12-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Funding Unavailable
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02988843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02988843, "Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02988843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*